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Summary
Background: Many organophosphorus (OP) insecti-
cides have either two O-methyl or two O-ethyl
groups attached to the phosphorus atom. This chem-
ical structure affects their responsiveness to oxime-
induced acetylcholinesterase (AChE) reactivation
after poisoning. However, several OP insecticides
are atypical and do not have these structures.
Aim: We aimed to describe the clinical course
and responsiveness to therapy of people poisoned
with two S-alkyl OP insecticides—profenofos and
prothiofos.
Design: We set up a prospective cohort of patients
with acute profenofos or prothiofos self-poisoning
admitted to acute medical wards in two Sri Lankan
district hospitals. Clinical observation was carried
out throughout their inpatient stay; blood samples
were taken in a subgroup for assay of cholines-
terases and insecticide.
Results: Ninety-five patients poisoned with profeno-
fos and 12 with prothiofos were recruited over 5
years. Median time to admission was 4 (IQR 3–7)
h. Eleven patients poisoned with profenofos died
(11/95; 11.6%, 95% CI 5.9–20); one prothiofos
patient died (1/12; 8.3%, 95% CI 0.2–38). Thirteen
patients poisoned with profenofos required intuba-
tion for respiratory failure (13/95; 13.7%, 95% CI
7.5–22); two prothiofos-poisoned patients required
intubation. Both intubations and death occurred late
compared with other OP insecticides. Prolonged
ventilation was needed in those who survived—a
median of 310 (IQR 154–349) h. Unexpectedly,
red cell AChE activity on admission did not correlate
with clinical severity—all patients had severe AChE
inhibition (about 1% of normal) but most had only
mild cholinergic features, were conscious, and did
not require ventilatory support.
Conclusions: Compared with other commonly used
OP insecticides, profenofos and prothiofos are of
moderately severe toxicity, causing relatively
delayed respiratory failure and death. There was
no apparent response to oxime therapy. The lack
of correlation between red cell AChE activity
and clinical features suggests that this parameter
may not always be a useful marker of synaptic
AChE activity and severity after OP pesticide
poisoning.
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Pesticide self-poisoning is a major global health
problem, killing 250–350000 people each year.
1,2
Organophosphorus (OP) insecticide poisoning is a
particularly severe problem, accounting for around
2/3 of deaths.
3
The majority of OP insecticides can be
grouped according to their chemical structure as a
diethoxy OP [with two O–C2H5 groups attached
to the phosphorus that binds to and inhibits acetyl-
cholinesterase (AChE)] or a dimethoxy OP (with
two O–CH3 groups) (see Figure 2 of Eddleston
et al.
4). The identity of these alkyl groups has funda-
mental effects on the pharmacodynamics of poison-
ing and treatment, determining to a large extent
whether oximes effectively reactivate OP-inhibited
AChE.
4,5
However, a few OP insecticides do not fit
into these categories, including profenofos and
prothiofos (Figure 1). Both are highly lipid solu-
ble, moderately toxic OP insecticides. Of note,
they have an S-alkyl (S–C3H7) group attached
to the phosphorus, in addition to the more typical
O–C2H5 group. Although in vitro studies with
human red cells have been done,
6,7 the conse-
quences of this different structure on AChE inhibi-
tion and reactivation with oximes in vivo are
unknown. We therefore prospectively studied
patients with a history of S-alkyl OP poisoning to
better understand its clinical course. Cholinesterase
inhibition and re-activation with pralidoxime was
studied in a subgroup of profenofos poisoned
patients.
Materials and Methods
Patients
Study patients were consecutive patients admitted to
two Sri Lankan hospitals with a history of acute poi-
soning with profenofos 50% emulsifiable concen-
trate (EC50) or prothiofos EC50, as indicated by
the patient or relatives, the transferring doctor or
the pesticide bottle. We have previously noted the
ingestion history to be highly accurate.
4,8 They
formed part of a cohort from which patients were
recruited to RCTs of routine activated charcoal
administration (ISRCTN02920054) and high-dose
pralidoxime (ISRCTN-55264358) that showed no
effect.
9,10 Ethics approval was obtained from the
Oxfordshire Clinical Research Ethics Committee
and Faculty of Medicine Ethics Committee,
Colombo.
Patients were treated using a standard protocol
that has been described earlier.
4,11 They were resus-
citated with fluids and atropine to raise the systolic
blood pressure above 80mmHg, the heart rate
above 80 b.p.m. and clear the lungs of audible
secretions and wheeze. Symptomatic patients
who required atropine initially received pralidoxime
chloride 1g q6h for 1–3 days. From May 2004,
symptomatic patients requiring atropine were
eligible for an RCT of high-dose pralidoxime chlo-
ride (2g loading dose over 20min followed by
0.5g/h for up to 7 days, or until atropine had not
been required for 12–24h) vs. saline placebo. Three
profenofos poisoned patients were recruited; symp-
tomatic patients not recruited to the trial received
pralidoxime chloride 1g q6h for 1–3 days.
A
B
Figure 1. Characteristics and structure of (A) profenofos and (B) prothiofos.
786 M. Eddleston et al.Patients remained under the care of the consultant
physicians. Management protocols were agreed
between the ward doctors and study team.
Decisions about intubation and transfer of patients
to intensive care were made by the medical team
independently of the study doctors. All decisions
were made on the basis of the patient’s clinical con-
dition and not the particular OP ingested.
All patients were seen regularly by full time study
doctors at least every 3h and more according to
clinical need. Significant events (intubation, seizures
and death) were recorded at the time of the event.
Patients were also seen on a study ward round twice
each day and their condition over the previous 12h
were recorded. We did not produce a Poison
Severity Score
12 routinely for patients; in a previous
study, we noted that the Glasgow Coma Score (GCS)
was as good as the Poison Severity Score in predict-
ing outcome.
13
Patients were first managed on the medical ward.
Seriously ill patients, as judged by the ward’s med-
ical staff on basis of GCS and cardiorespiratory func-
tion, were transferred to the intensive care unit (ICU)
as beds became available. Each hospital had 2–8
ICU beds for medical patients; there was always dif-
ficulty in obtaining a bed. This article describes all
patients with S-alkyl poisoning, whether they were
admitted to ICU or not.
Criteria for intubation were tidal volume <180ml/
breath using a Wright’s respirometer, respiratory rate
<10 breaths/min or failure of a Guedel airway to
preserve airway patency. Arterial blood gases were
not available to guide therapy; pulse oximetry was
sometimes available. Hypotensive patients, not
responding to atropine and fluid resuscitation,
were treated with high doses of dopamine plus
dobutamine as necessary by infusion pump.
Norepinephrine and epinephrine infusions were
not used; bolus epinephrine was administered for
cardiac arrest.
Toxicological analysis
Blood samples were taken on admission, and at reg-
ular intervals thereafter, from patients recruited to
the pralidoxime RCT and from patients admitted
during two periods (9 May–10 July 2002 and 2–26
December 2002). Lab assay capacity limited the
sample number that could be handled and deter-
mined the short period of sampling.
For red cell AChE measurement, 0.2ml of EDTA
blood was diluted at the bedside into 4ml of cooled
saline and rapidly frozen to –208C. Red cell AChE
activity is usually 600–700 mU/mmol Hb; a small
study of Caucasians reported a mean of 65118
mU/mmol Hb.
14 We selected a value of 600 mU/
mmol Hb to be the lower limit of normal for this
study. Plasma was then separated from a second
EDTA blood sample and frozen at –208C. All anal-
yses were done in Munich. AChE activity
was assayed according to a modified Ellman
method, using ethopropazine to inhibit butyrylcho-
linesterase (BuChE) activity.
14 Re-activatability of
AChE (ageing) and BuChE were assessed as
described.
5,14A median BuChE value of 6000
mU/ml was taken as normal for this study.
15
Profenofos was quantified in plasma by gas chroma-
tography with a lower limit of quantitation of 0.05
nmol/ml plasma.
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Figure 2. (A) Timing of intubation; (B) duration of ventilation and (C) timing of death post-ingestion in profenofos and
prothiofos poisoned patients. For 2C, patients were separated according to whether they were intubated (circles) or not
(squares) before death.
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Data analysis was performed in Prism v4. Clinical
characteristics were summarized using counts (per-
centages) for categorical variables and the median
[interquartile range (IQR)] for non-normally distrib-
uted continuous variables.
Results
Between 31 March 2002 and 26 March 2007,
14034 patients with acute poisoning were prospec-
tively reviewed on admission to Anuradhapura and
Polonnaruwa General Hospitals, Sri Lanka. One
hundred and seven had ingested an S-alkyl OP
insecticide—95 profenofos and 12 prothiofos.
The median age of the patients was 32 years (IQR
24–45); 82 (76.6%) were male. They presented a
median of 4h (IQR 3–7) post-ingestion. Fifty-seven
(53.3%) had previously received atropine; of these
patients 11 (10.3% of all patients) had received pra-
lidoxime chloride in the transferring hospital. On
admission to the secondary hospital, around one-
third (37/107; 34.6%) were symptomatic, requiring
atropine for cholinergic features. However, very
few were severely poisoned with reduced
consciousness
13—median GCS was high (15/15;
IQR 15–15) with only 8/107 having a GCS <9.
Mortality and respiratory failure
Eleven patients poisoned with profenofos died (11/
95; 11.6%, 95% CI 5.9–20); one prothiofos patient
died (1/12; 8.3%, 95% CI 0.2–38). Deaths from pro-
fenofos poisoning occurred in a median of 29 (IQR
17–113) h post-ingestion (Figure 2C); none occurred
within 11h of ingestion. The death from prothiofos
occurred 67h post-ingestion.
Thirteen patients poisoned with profenofos
required intubation for a low tidal volume
(<180ml/breath), bradypnoea, or failure of a
Guedel airway to preserve airway patency (13/95;
13.7%, 95% CI 7.5–22). Two prothiofos-poisoned
patients required intubation (2/12; 16.7% 95% CI
2.1–48). Intubation for profenofos poisoning
occurred in a median of 9.2 (IQR 5.2–26) h post-
ingestion (Figure 2A). Seven intubated patients with
profenofos poisoning (7/13, 53.8%) survived. The
two intubations for prothiofos poisoning occurred
11 and 30h post-ingestion; one intubated patient
survived. Of the seven profenofos-poisoned patients
who survived, median duration of ventilation was
320h (IQR 140–353) (Figure 2B). The intubated
patient with prothiofos poisoning who survived
was intubated for 300h.
Cholinesterase inhibition and reactivation
Cholinesterases were assayed in 10 patients with
profenofos poisoning (Figure 3). Proof of profenofos
exposure was sought and found in five patients.
Median plasma concentration in admission samples
was 3.35 (range 0.67–7.31) mmol/l.
Red cell AChE was almost completely inhibited
on admission, with a median activity of 7 (IQR 1–
30) mU/mmol Hb—approximately 1% of normal
activity (Figure 3A). Remarkably, unlike dimethoxy
and diethoxy OP poisoning,
16 there was no re-
activation of red cell AChE [median activity at base-
line: 25 (IQR 3.5–81) mU/mmol Hb; median activity
at 1-h post-pralidoxime: 19 (IQR 8–33) mU/mmol
Hb] in the four patients who received 1–2g loading
dose of pralidoxime.
This lack of response to oximes suggested that
nearly all the inhibited red cell AChE was already
aged on admission. In vitro assays with very high
doses of obidoxime
14 confirmed that the enzyme
was aged: median non-aged red cell AChE at base-
line was 25 (IQR 9–100) mU/mmol Hb (Figure 3B),
indicating that > 95% of red cell AChE was aged.
BuChE was similarly completely inhibited on
admission. Median plasma BuChE on admission in
the 10 patients was 33 (IQR 9–73) mU/ml, <1% of
estimated normal activity. It started to rise after 2–3
days as inhibitory activity in plasma faded (Figure 3).
Despite such severe red cell AChE inhibition,
these patients were very well on admission. Only
two of the 10 had a GCS score less than 15/15 on
admission; two patients had no symptoms of poison-
ing after receiving bolus doses of atropine in the
transferring hospital. This is surprising considering
the generally held view that red cell AChE activity
is a good marker of neuromuscular function in OP
poisoning.
17
Discussion
This study shows that the S-alkyl OP insecticides
profenofos and prothiofos are likely to be of moder-
ately severe toxicity as emulsifiable concentrates,
lying between high toxicity OPs such as dimethoate
and monocrotophos and lower toxicity OPs such as
chlorpyrifos.
4,18 However, most importantly and
unexpectedly, many patients were well on admis-
sion and none required immediate intubation,
despite (in profenofos poisoned patients) almost
complete inhibition of red cell AChE activity. Few
subsequently required intubation, and both intuba-
tion and death occurred late compared with other
OPs.
4 This is very different to chlorpyrifos and qui-
nalphos poisoning in which red cell AChE is also
788 M. Eddleston et al.severely inhibited on admission,
4,16 but the majority
of intubations occur at this time.
19
The reason for this remarkable discordance
between red cell AChE activity and clinical picture
on presentation in profenofos poisoning is unclear.
Clinical presentation results from AChE inhibition in
tissues other than the blood, particularly the neuro-
muscular junction and CNS. It is possible that pro-
fenofos does not penetrate the CNS. One rat study
has reported that severe blood cholinesterase inhi-
bition was associated with only mild CNS AChE
inhibition after profenofos poisoning.
20 However,
blood cholinesterase activity reported for control
animals in this article was very low, suggesting
methodological problems. The high partition coeffi-
cient for the OPs (Figure 1) should not preclude
them from penetrating the CNS.
21 Furthermore, the
clinical severity of profenofos poisoning correlated
with brain AChE activity in a study of chickens.
22
Another explanation may relate to differential tox-
icity of the chiral profenofos enantiomers. In vitro,
the (+)-profenofos enantiomer inhibits AChE 23-fold
more potently than the (–)-enantiomer, while the
(–)-enantiomer is 23-fold more potent in vivo.
23
The reason for this dichotomy was attributed to
stereo-specific metabolism in vivo with preferential
oxidative activation of the (–)-enantiomer to a more
potent inhibitor of AChE than the non-activated (+)-
enantiomer.
24 This putative active metabolite has
been tentatively assigned a phosphorothiolate
S-oxide structure (R–S(O)–P(O)–).
25 It has not
been isolated because it rapidly converts to the
phosphinyl-oxysulfenate (R–S–O–P(O)–), which is
unlikely to be a phosphorylating agent.
24,25
Hence, the putative highly active S-oxide metabolite
resembles a fast-acting ‘hit-and-run’ compound.
AChE inhibited by the (+)-profenofos enantiomer
or (–)-phosphorothiolate S-oxide shows very differ-
ent post-inhibitory reactions. While the former
yields an enzyme that undergoes rapid spontaneous
and oxime-induced reactivation, AChE inhibited by
the latter ages rapidly and is refractory to re-
activation.
22,26 If these rapid reactions occur in the
blood under physiological conditions, we hypothe-
size that the (–)-profenofos S-oxide is used up in
venous blood and does not appear in arterial
blood. Consequently, neuronal AChE inhibition
will result from the action of the (+)-enantiomer of
profenofos. This compound, although a potent AChE
inhibitor, shows rather rapid spontaneous re-
activation that is similar to dimethoxyphosphoryl–
AChE. Hence, inhibition of AChE will gradually
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Figure 3. Cholinesterase inhibition in 10 profenofos patients. Inhibition of both cholinesterases was nearly complete on
admission; there was no response to loading doses of 1–2g of pralidoxime chloride. Three patients subsequently died.
(A) In vivo AChE activity; (B) Ex vivo AChE activity showing non-aged AChE; (C) BuChE activity; (D) AChE inhibitory activity
in plasma, indicating presence of active OP. Few samples were available after 72h. Mean  SD.
Profenofos and prothiofos organophosphorus poisoning 789fade and residual AChE-activity may remain at a
level that does not cause severe poisoning.
This hypothesis may explain the presence of
almost completely inhibited and aged red cell
AChE in patients with mild cholinergic toxicity
soon after profenofos ingestion. It also suggests that
oximes may be clinically useful despite complete
red cell AChE ageing. However, experimental
proof is required to test this hypothesis. This
should be possible by measuring profenofos enan-
tiomers in matched venous and arterial blood sam-
ples from profenofos poisoned animals or humans,
and measuring the neuromuscular function and the
response to oximes.
Of note, our findings indicate that red cell AChE
activity may not always be an accurate marker of
synaptic function or OP poisoning severity, as we
and others have proposed previously.
16,17,27,28 The
evidence for the usefulness of red cell AChE as a
marker in OP pesticide poisoning is limited. An
unpublished retrospective study in 16 patients
demonstrated that red cell AChE correlated with
plasma atropine concentration and presumably
AChE activity in muscarinic synapses.
29A neuro-
physiological study in 34 patients showed that it
correlated with patterns of neuromuscular transmis-
sion.
28 Both studies included patients taking a vari-
ety of diethoxy and dimethoxy OPs. There is a lack
of studies reporting a useful correlation between red
cell AChE and clinical severity.
Neither profenofos nor prothiofos poisoning
appears to be a major clinical problem. There are
just four case reports, all fatal, in the literature.
30–33
Three other papers have reported cases in India,
18
Nepal
34 and Taiwan.
35 This case series is by far the
biggest published to date. Acephate (CAS 30560-19-
1) and methamidophos (CAS 10265-92-6) are the
two other S-alkyl OPs, the latter a metabolite
of the former. Whilst acephate poisoning appears
to be uncommon, with relatively few case
reports,
18,36,37 methamidophos is highly toxic and
has killed many people in Sri Lanka,
38 Taiwan
35
and China.
39–41 Although in vitro studies have
been done,
6,24 no in vivo human data have been
published about cholinesterase inhibition with
these S-alkyl OPs.
Limitations of this article include the small
number of prothiofos-poisoned patients, lack of
AChE activity data for these patients, and the lack
of facilities for close monitoring of patients that
might have allowed better description of cause of
death. In addition, the number of profenofos-
poisoned patients recruited to the RCT and therefore
having their blood cholinesterase and plasma OP
measured was small. However, the very low AChE
activity in this group was very consistent and there
appears no reason to think that they are unrepresen-
tative of the whole case series.
Conclusion
Self-poisoning with the S-alkyl OPs profenofos and
prothiofos is moderately dangerous when compared
with other OP pesticides. Most importantly, red cell
AChE activity in profenofos-poisoned patients is not
re-activated by pralidoxime and did not correlate
with clinical severity, suggesting that this marker
may not be generally valid for OP poisoning.
It will be useful now to find ways of measuring
CNS AChE activity, alongside neuromuscular and
red cell AChE activity, in animal models of OP poi-
soning and human patients to determine the relative
role of each enzyme.
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